Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Energy balance related lifestyle factors and risk of endometrial and colorectal cancer among individuals with lynch syndrome: a systematic review.

Coletta AM, Peterson SK, Gatus LA, Krause KJ, Schembre SM, Gilchrist SC, Pande M, Vilar E, You YN, Rodriguez-Bigas MA, Strong LL, Lynch PM, Lu KH, Basen-Engquist K.

Fam Cancer. 2019 Jun 24. doi: 10.1007/s10689-019-00135-7. [Epub ahead of print] Review.

PMID:
31236808
2.

Outcomes of disease-specific next-generation sequencing gene panel testing in adolescents and young adults with colorectal cancer.

Mork ME, Rodriguez A, Bannon SA, Lynch PM, Rodriguez-Bigas MA, Thirumurthi S, You YN, Vilar E.

Cancer Genet. 2019 Jun;235-236:77-83. doi: 10.1016/j.cancergen.2019.04.064. Epub 2019 Apr 26.

PMID:
31101557
3.

Health and lifestyle behaviors in colorectal cancer survivors with and without Lynch syndrome.

Donato KM, Moore K, Parker WM, Peterson SK, Gritz ER, Amos CI, Lu KH, Lynch PM, Rodriguez-Bigas MA, You YN, Burton-Chase AM.

J Community Genet. 2019 Apr 23. doi: 10.1007/s12687-019-00421-y. [Epub ahead of print]

PMID:
31016603
4.

Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.

You YN, Borras E, Chang K, Price BA, Mork M, Chang GJ, Rodriguez-Bigas MA, Bednarski BK, Meric-Bernstam F, Vilar E.

Dis Colon Rectum. 2019 Apr;62(4):429-437. doi: 10.1097/DCR.0000000000001322.

PMID:
30730459
5.

Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features.

Jiang W, Cai MY, Li SY, Bei JX, Wang F, Hampel H, Ling YH, Frayling IM, Sinicrope FA, Rodriguez-Bigas MA, Dignam JJ, Kerr DJ, Rosell R, Mao M, Li JB, Guo YM, Wu XY, Kong LH, Tang JH, Wu XD, Li CF, Chen JR, Ou QJ, Ye MZ, Guo FM, Han P, Wang QW, Wan DS, Li L, Xu RH, Pan ZZ, Ding PR; Written on behalf of AME Colorectal Cancer Cooperative Group.

Int J Cancer. 2019 May 1;144(9):2161-2168. doi: 10.1002/ijc.32044. Epub 2019 Jan 9.

PMID:
30521064
6.

Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma.

Holliday EB, Hunt A, You YN, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Bednarski BK, Eng C, Koay EJ, Minsky BD, Taniguchi C, Krishnan S, Herman JM, Das P.

J Gastrointest Oncol. 2017 Dec;8(6):990-997. doi: 10.21037/jgo.2017.09.02.

7.

Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Biliary Tract Cancers Associated with Lynch Syndrome.

Cloyd JM, Chun YS, Ikoma N, Vauthey JN, Aloia TA, Cuddy A, Rodriguez-Bigas MA, Nancy You Y.

J Gastrointest Cancer. 2018 Mar;49(1):93-96. doi: 10.1007/s12029-017-0040-9.

PMID:
29238914
8.

Assessment of Ileostomy Output Using Telemedicine: A Feasibility Trial.

Bednarski BK, Slack RS, Katz M, You YN, Papadopolous J, Rodriguez-Bigas MA, Skibber JM, Matin SF, Chang GJ.

Dis Colon Rectum. 2018 Jan;61(1):77-83. doi: 10.1097/DCR.0000000000000945.

PMID:
29215474
9.

Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis.

Gunther JR, Chadha AS, Shin US, Park IJ, Kattepogu KV, Grant JD, Weksberg DC, Eng C, Kopetz SE, Das P, Delclos ME, Kaur H, Maru DM, Skibber JM, Rodriguez-Bigas MA, You YN, Krishnan S, Chang GJ.

Adv Radiat Oncol. 2017 Apr 12;2(3):455-464. doi: 10.1016/j.adro.2017.04.001. eCollection 2017 Jul-Sep.

10.

In Silico Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation.

Borras E, Chang K, Pande M, Cuddy A, Bosch JL, Bannon SA, Mork ME, Rodriguez-Bigas MA, Taggart MW, Lynch PM, You YN, Vilar E.

Cancer Prev Res (Phila). 2017 Oct;10(10):580-587. doi: 10.1158/1940-6207.CAPR-17-0058. Epub 2017 Aug 1.

11.

Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.

Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, Kopetz S, Messick C, Skibber JM, Chang GJ.

J Clin Oncol. 2017 Aug 10;35(23):2631-2638. doi: 10.1200/JCO.2016.72.1464. Epub 2017 Jun 28.

12.

Timing of Surgical Resection for Curative Colorectal Cancer with Liver Metastasis.

Ali SM, Pawlik TM, Rodriguez-Bigas MA, Monson JRT, Chang GJ, Larson DW.

Ann Surg Oncol. 2018 Jan;25(1):32-37. doi: 10.1245/s10434-016-5745-7. Epub 2017 Feb 21. Review.

PMID:
28224365
13.

A comparison between Lynch syndrome and sporadic colorectal cancer survivors' satisfaction with their healthcare providers.

Burton-Chase AM, Parker WM, Polivka KM, Gritz ER, Amos CI, Lu KH, Lynch PM, Rodriguez-Bigas MA, Nancy You Y, Peterson SK.

Cancer Med. 2017 Mar;6(3):698-707. doi: 10.1002/cam4.1033. Epub 2017 Feb 17.

14.

Health-related quality of life in colorectal cancer survivors: are there differences between sporadic and hereditary patients?

Burton-Chase AM, Parker WM, Donato KM, McCormick S, Gritz ER, Amos CI, Lu KH, Lynch PM, Rodriguez-Bigas MA, Nancy You Y, Peterson SK.

J Patient Rep Outcomes. 2017;2(1):21. doi: 10.1186/s41687-018-0047-4. Epub 2018 May 1.

15.

Identification of MSH2 inversion of exons 1-7 in clinical evaluation of families with suspected Lynch syndrome.

Mork ME, Rodriguez A, Taggart MW, Rodriguez-Bigas MA, Lynch PM, Bannon SA, You YN, Vilar E.

Fam Cancer. 2017 Jul;16(3):357-361. doi: 10.1007/s10689-016-9960-y.

16.

Anal Dysplasia.

Messick CA, Rodriguez-Bigas MA.

Surg Oncol Clin N Am. 2017 Jan;26(1):33-43. doi: 10.1016/j.soc.2016.07.005. Review.

PMID:
27889035
17.

Locally Recurrent Disease Related to Anal Canal Cancers.

Sammour T, Rodriguez-Bigas MA, Skibber JM.

Surg Oncol Clin N Am. 2017 Jan;26(1):115-125. doi: 10.1016/j.soc.2016.07.006. Review.

PMID:
27889030
18.

Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer.

Liu C, Eng C, Shen J, Lu Y, Takata Y, Mehdizadeh A, Chang GJ, Rodriguez-Bigas MA, Li Y, Chang P, Mao Y, Hassan MM, Wang F, Li D.

Oncotarget. 2016 Nov 15;7(46):76250-76260. doi: 10.18632/oncotarget.12841.

19.

Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation.

Osborne EM, Eng C, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Nancy You YQ, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das P.

Am J Clin Oncol. 2018 Jul;41(7):632-637. doi: 10.1097/COC.0000000000000338.

PMID:
27755060
20.

Comparative effectiveness of primary tumor resection in patients with stage IV colon cancer.

Alawadi Z, Phatak UR, Hu CY, Bailey CE, You YN, Kao LS, Massarweh NN, Feig BW, Rodriguez-Bigas MA, Skibber JM, Chang GJ.

Cancer. 2017 Apr 1;123(7):1124-1133. doi: 10.1002/cncr.30230. Epub 2016 Aug 1.

21.

DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.

de Rosa N, Rodriguez-Bigas MA, Chang GJ, Veerapong J, Borras E, Krishnan S, Bednarski B, Messick CA, Skibber JM, Feig BW, Lynch PM, Vilar E, You YN.

J Clin Oncol. 2016 Sep 1;34(25):3039-46. doi: 10.1200/JCO.2016.66.6826. Epub 2016 Jul 18.

22.

Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy.

Park IJ, You YN, Skibber JM, Rodriguez-Bigas MA, Das P, Eng C, Kopetz S, Wolff RA, Crane CH, Krishnan S, Minsky B, Hu CY, Nguyen S, Chang GJ.

Am J Clin Oncol. 2017 Jun;40(3):277-282. doi: 10.1097/COC.0000000000000150.

23.

Identification of a novel PMS2 alteration c.505C>G (R169G) in trans with a PMS2 pathogenic mutation in a patient with constitutional mismatch repair deficiency.

Mork ME, Borras E, Taggart MW, Cuddy A, Bannon SA, You YN, Lynch PM, Ramirez PT, Rodriguez-Bigas MA, Vilar E.

Fam Cancer. 2016 Oct;15(4):587-91. doi: 10.1007/s10689-016-9902-8.

24.

Impact of multimodal therapy in locally recurrent rectal cancer.

You YN, Skibber JM, Hu CY, Crane CH, Das P, Kopetz ES, Eng C, Feig BW, Rodriguez-Bigas MA, Chang GJ.

Br J Surg. 2016 May;103(6):753-762. doi: 10.1002/bjs.10079. Epub 2016 Mar 2.

25.

High Prevalence of Hereditary Cancer Syndromes in Adolescents and Young Adults With Colorectal Cancer.

Mork ME, You YN, Ying J, Bannon SA, Lynch PM, Rodriguez-Bigas MA, Vilar E.

J Clin Oncol. 2015 Nov 1;33(31):3544-9. doi: 10.1200/JCO.2015.61.4503. Epub 2015 Jul 20.

26.

A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer.

Dineen S, Lynch PM, Rodriguez-Bigas MA, Bannon S, Taggart M, Reeves C, Modaro C, Overman M, Chang GJ, Skibber JM, You YN.

J Natl Compr Canc Netw. 2015 Jul;13(7):865-72.

PMID:
26150580
27.

Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains.

Kneuertz PJ, Chang GJ, Hu CY, Rodriguez-Bigas MA, Eng C, Vilar E, Skibber JM, Feig BW, Cormier JN, You YN.

JAMA Surg. 2015 May;150(5):402-9. doi: 10.1001/jamasurg.2014.3572.

PMID:
25806815
28.

Reply to N.H. Turner et al and Ł. Dziki et al.

Massarweh NN, Hu CY, Rodriguez-Bigas MA, Chang GJ.

J Clin Oncol. 2015 Apr 20;33(12):1412-3. doi: 10.1200/JCO.2014.59.9399. Epub 2015 Mar 23. No abstract available.

PMID:
25800769
29.

An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.

Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E.

Gut. 2016 Feb;65(2):286-95. doi: 10.1136/gutjnl-2014-307235. Epub 2015 Mar 19.

30.

Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival.

Hu CY, Bailey CE, You YN, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ.

JAMA Surg. 2015 Mar 1;150(3):245-51. doi: 10.1001/jamasurg.2014.2253.

PMID:
25588105
31.

Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer.

Vilar E, Mork ME, Cuddy A, Borras E, Bannon SA, Taggart MW, Ying J, Broaddus RR, Luthra R, Rodriguez-Bigas MA, Lynch PM, You YQ.

Cancer Genet. 2014 Oct-Dec;207(10-12):495-502. doi: 10.1016/j.cancergen.2014.10.002. Epub 2014 Oct 13.

32.

Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010.

Bailey CE, Hu CY, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJ.

JAMA Surg. 2015 Jan;150(1):17-22. doi: 10.1001/jamasurg.2014.1756. Erratum in: JAMA Surg. 2015 Mar 1;150(3):277.

33.

Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum.

Sturgeon JD, Crane CH, Krishnan S, Minsky BD, Skibber JM, Rodriguez-Bigas MA, Chang GJ, You YN, Eng C, Das P.

Am J Clin Oncol. 2017 Apr;40(2):163-166. doi: 10.1097/COC.0000000000000126.

PMID:
25222072
34.

Functional deficits and symptoms of long-term survivors of colorectal cancer treated by multimodality therapy differ by age at diagnosis.

Bailey CE, Tran Cao HS, Hu CY, Chang GJ, Feig BW, Rodriguez-Bigas MA, Nguyen ST, Skibber JM, You YN.

J Gastrointest Surg. 2015 Jan;19(1):180-8; discussio 188. doi: 10.1007/s11605-014-2645-7. Epub 2014 Sep 12.

35.

Risk-adjusted pathologic margin positivity rate as a quality indicator in rectal cancer surgery.

Massarweh NN, Hu CY, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Cormier JN, Feig BW, Chang GJ.

J Clin Oncol. 2014 Sep 20;32(27):2967-74.

36.

Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: ten-year institutional experience.

Hyngstrom JR, Tzeng CW, Beddar S, Das P, Krishnan S, Delclos ME, Crane CH, Chang GJ, You YN, Feig BW, Skibber JM, Rodriguez-Bigas MA.

J Surg Oncol. 2014 Jun;109(7):652-8. doi: 10.1002/jso.23570. Epub 2014 Feb 10.

PMID:
24510523
37.

Patient-reported disease knowledge and educational needs in Lynch syndrome: findings of an interactive multidisciplinary patient conference.

Bannon SA, Mork M, Vilar E, Peterson SK, Lu K, Lynch PM, Rodriguez-Bigas MA, You YN.

Hered Cancer Clin Pract. 2014 Feb 5;12(1):1. doi: 10.1186/1897-4287-12-1.

38.

Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007.

Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJ.

Cancer. 2014 Apr 15;120(8):1162-70. doi: 10.1002/cncr.28545. Epub 2014 Jan 28.

39.

Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.

Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):301-5. doi: 10.1016/j.ijrobp.2013.10.034. Epub 2013 Dec 5.

40.

Metformin use and improved response to therapy in rectal cancer.

Skinner HD, Crane CH, Garrett CR, Eng C, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Kelly P, Sandulache VC, Delclos ME, Krishnan S, Das P.

Cancer Med. 2013 Feb;2(1):99-107. doi: 10.1002/cam4.54. Epub 2013 Feb 3.

41.

Impact of ileostomy-related complications on the multidisciplinary treatment of rectal cancer.

Phatak UR, Kao LS, You YN, Rodriguez-Bigas MA, Skibber JM, Feig BW, Nguyen S, Cantor SB, Chang GJ.

Ann Surg Oncol. 2014 Feb;21(2):507-12. doi: 10.1245/s10434-013-3287-9. Epub 2013 Oct 2.

42.

Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.

Eng C, Chang GJ, You YN, Das P, Xing Y, Delclos M, Wolff RA, Rodriguez-Bigas MA, Skibber J, Ohinata A, Gould S, Phillips J, Crane CH.

Cancer. 2013 Nov 1;119(21):3769-75. doi: 10.1002/cncr.28296. Epub 2013 Aug 20.

43.

A novel risk-adjusted nomogram for rectal cancer surgery outcomes.

Russell MC, You YN, Hu CY, Cormier JN, Feig BW, Skibber JM, Rodriguez-Bigas MA, Nelson H, Chang GJ.

JAMA Surg. 2013 Aug;148(8):769-77. doi: 10.1001/jamasurg.2013.2136.

44.

An individualized conditional survival calculator for patients with rectal cancer.

Bowles TL, Hu CY, You NY, Skibber JM, Rodriguez-Bigas MA, Chang GJ.

Dis Colon Rectum. 2013 May;56(5):551-9. doi: 10.1097/DCR.0b013e31827bd287.

45.

Surgical treatment of hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome).

Rodriguez-Bigas MA, Möeslein G.

Fam Cancer. 2013 Jun;12(2):295-300. doi: 10.1007/s10689-013-9626-y. Review.

PMID:
23508345
46.

Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool.

Lynch PM, Morris JS, Ross WA, Rodriguez-Bigas MA, Posadas J, Khalaf R, Weber DM, Sepeda VO, Levin B, Shureiqi I.

Gastrointest Endosc. 2013 Mar;77(3):455-63. doi: 10.1016/j.gie.2012.11.038. Epub 2013 Jan 18.

47.

Superior mesenteric artery syndrome after ileal pouch anal anastomosis.

Truong AR, Rodriguez-Bigas MA, Nguyen ST, Kaur H, Ernst RD, You YN.

Am Surg. 2013 Jan;79(1):E14-6. No abstract available.

PMID:
23317590
48.

Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.

Park IJ, You YN, Skibber JM, Rodriguez-Bigas MA, Feig B, Nguyen S, Hu CY, Chang GJ.

Dis Colon Rectum. 2013 Feb;56(2):135-41. doi: 10.1097/DCR.0b013e318278ff8a.

49.

Multimodality salvage of recurrent disease after local excision for rectal cancer.

You YN, Roses RE, Chang GJ, Rodriguez-Bigas MA, Feig BW, Slack R, Nguyen S, Skibber JM.

Dis Colon Rectum. 2012 Dec;55(12):1213-9. doi: 10.1097/DCR.0b013e318270837f.

PMID:
23135578
50.

Morbidity of staged proctectomy after hepatectomy for colorectal cancer: a matched case-control analysis.

Tzeng CW, Aloia TA, Vauthey JN, Chang GJ, Ellis LM, Feig BW, Curley SA, Skibber JM, Abdalla EK, You YN, Rodriguez-Bigas MA.

Ann Surg Oncol. 2013 Feb;20(2):482-90. doi: 10.1245/s10434-012-2620-z. Epub 2012 Aug 30.

PMID:
22932858

Supplemental Content

Loading ...
Support Center